VEGFA and retinopathy of prematurity: It is at this point that intravitreous anti-VEGF agents can be given to effectively treat severe ROP.52, –54 VEGF production can be stimulated by hypoxia, but systemic diseases, oxygen treatment and respiratory distress might also trigger VEGF production and release.55 From this we infer that maintenance of higher VEGF levels during the ROP prephase or phase 1 would be reflective of less vasocessation, and thus might reduce ROP risk.